Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Larsen

Showing results (1251-1260 of 1,301) with videos related to

Pageof 131
Sort By:
Clinical Epidemiology|December 10, 2019
Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing ChemotherapyMichael R Clausen, Matthew J Maurer, Sinna Pilgaard Ulrichsen, et al.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
Scientific Reports|March 4, 2017
Shrubland primary production and soil respiration diverge along European climate gradientSabine Reinsch, Eva Koller, Alwyn Sowerby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancerS Chowdhury, A Bjartell, N Agarwal, et al.
The New England Journal of Medicine|June 1, 2019
Apalutamide for Metastatic, Castration-Sensitive Prostate CancerKim N Chi, Neeraj Agarwal, Anders Bjartell, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 16, 2025
Cognition varies across the calendar year in multiple large-scale datasetsArielle S Keller, Alisha Shetty, Ran Barzilay, et al.
Acta Dermato-Venereologica|January 1, 1997
Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-upE L Svejgaard, F Brandrup, K Kragballe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyKim N Chi, Simon Chowdhury, Anders Bjartell, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2023
Mapping the relationship of white matter lesions to depression in multiple sclerosisErica B Baller, Elizabeth M Sweeney, Matthew C Cieslak, et al.
Biological Psychiatry|November 19, 2023
Mapping the Relationship of White Matter Lesions to Depression in Multiple SclerosisErica B Baller, Elizabeth M Sweeney, Matthew Cieslak, et al.
Pageof 131

Showing results (1251-1260 of 1,301) with videos related to

Sort By:
Pageof 131
Clinical Epidemiology|December 10, 2019
Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing ChemotherapyMichael R Clausen, Matthew J Maurer, Sinna Pilgaard Ulrichsen, et al.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
Scientific Reports|March 4, 2017
Shrubland primary production and soil respiration diverge along European climate gradientSabine Reinsch, Eva Koller, Alwyn Sowerby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancerS Chowdhury, A Bjartell, N Agarwal, et al.
The New England Journal of Medicine|June 1, 2019
Apalutamide for Metastatic, Castration-Sensitive Prostate CancerKim N Chi, Neeraj Agarwal, Anders Bjartell, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 16, 2025
Cognition varies across the calendar year in multiple large-scale datasetsArielle S Keller, Alisha Shetty, Ran Barzilay, et al.
Acta Dermato-Venereologica|January 1, 1997
Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-upE L Svejgaard, F Brandrup, K Kragballe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyKim N Chi, Simon Chowdhury, Anders Bjartell, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2023
Mapping the relationship of white matter lesions to depression in multiple sclerosisErica B Baller, Elizabeth M Sweeney, Matthew C Cieslak, et al.
Biological Psychiatry|November 19, 2023
Mapping the Relationship of White Matter Lesions to Depression in Multiple SclerosisErica B Baller, Elizabeth M Sweeney, Matthew Cieslak, et al.
Pageof 131